Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.224,53
0,33%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Beam Therapeutics Inc (BEAM) Beam Therapeutics Inc (BEAM) Notizie

Beam Therapeutics Inc

BEAM
24,59
-0,65 (-2,58%)
15 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/6/202409:00GLOBEBeam Therapeutics Reports Data Highlighting Optimized..
10/6/202422:30EDGAR2Form 8-K - Current report
07/6/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202412:30GLOBEBeam Therapeutics to Participate in Jefferies Global..
14/5/202422:00GLOBEBeam Therapeutics to Present Data Highlighting Robust..
08/5/202412:30GLOBEBeam Therapeutics to Participate in RBC Capital Markets 2024..
07/5/202413:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:09EDGAR2Form 8-K - Current report
07/5/202412:30GLOBEBeam Therapeutics Reports Pipeline Updates and First Quarter..
26/3/202411:30GLOBEBeam Therapeutics Announces Clearance of Clinical Trial..
28/2/202412:30GLOBEBeam Therapeutics to Participate in Upcoming March 2024..
27/2/202413:40EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202413:22EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202412:43EDGAR2Form 8-K - Current report
27/2/202412:30GLOBEBeam Therapeutics Reports Fourth Quarter and Year-End 2023..
05/2/202412:30GLOBEBeam Therapeutics to Participate in the Guggenheim..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:47EDGAR2Form 144 - Report of proposed sale of securities
08/1/202412:55EDGAR2Form 8-K - Current report
08/1/202412:30GLOBEBeam Therapeutics Highlights Progress Across Base Editing..
05/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202412:30GLOBEBeam Therapeutics to Present at the 42nd Annual J.P. Morgan..
14/12/202322:05EDGAR2Form 8-K - Current report
14/12/202312:30GLOBEBeam Therapeutics Appoints Biotech Executive Christi Shaw to..
20/11/202322:20EDGAR2Form 144 - Report of proposed sale of securities
08/11/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202313:00EDGAR2Form 8-K - Current report
08/11/202312:30GLOBEBeam Therapeutics to Participate in 2023 Jefferies London..
01/11/202321:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202311:59DJNBeam Therapeutics to Sell Rights in Verve Licensing Deal to..
31/10/202311:44EDGAR2Form 8-K - Current report
31/10/202311:00GLOBEBeam Announces Agreement for Lilly to Acquire Beam’s Opt-In..
30/10/202321:41EDGAR2Form 144 - Report of proposed sale of securities
25/10/202312:30GLOBEBeam Therapeutics Presents Preclinical Data Highlighting..
24/10/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202314:50EDGAR2Form 8-K - Current report
19/10/202314:45GLOBEBeam Therapeutics Announces Portfolio Prioritization and..
04/10/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202316:00GLOBEBeam Therapeutics Presents Preclinical Data Highlighting..
05/9/202312:30GLOBEBeam Therapeutics Announces First Patient Dosed in Phase 1/2..
31/8/202312:30GLOBEBeam Therapeutics to Participate in Upcoming September..
09/8/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:11EDGAR2Form 8-K - Current report
08/8/202312:30GLOBEBeam Therapeutics Reports Pipeline Updates and Second..
26/7/202300:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 25,02 Min: 24,595 Max: 25,41
Chiusura: 25,24

La tua Cronologia

NASDAQ
BEAM
Beam Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network